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A protease degrading type IV collagen was purified more than 8000-fold from human stomach carcinoma tissue. This 
protease degraded type IV collagen, while type I, II, III and V collagen, laminin, fibronectin, casein, albumin and hemo- 
globin were not affected. This enzyme had a pH optimum of pH 7.G8.0 and was inhibited completely by EDTA and 
o-phenanthroline, but not by seryl, thiol and carboxyl protease inhibitors. Furthermore, the molecular mas of this enzyme 
was estimated to be 1 MDa by Sepharose 6B column and HPLC-gel filtration. The molecular mass and substrate specific- 
ity of this metalloprotease from human carcinoma tissue indicate it to be a new protease. 
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1. INTRODUCTION 
It is supposed that the basement membrane 
plays an important role as a barrier against tumor 
invasion and metastasis [ 1,2]. Type IV collagen is 
one of the specific components in the basement 
membrane and reports have appeared concerning a 
protease which degrades type IV collagen, for ex- 
ample, from human skin fibroblast, human 
rheumatoid synovial fibroblast, human leukocyte 
granules, rat mast cell, rabbit bone and metastatic 
murine tumor cell culture medium [3-121. 
However, no investigation of type IV collagen- 
degrading proteases from human malignant tissue 
has been published. Here, we report on the 
purification and characterization of a new 
metalloprotease from human malignant tissue, 
Correspondence address: M. Tsuda, Department of 
Biochemistry, School of Medicine, Tokai University, Isehara, 
Kanagawa 259-l 1, Japan 
Abbreviations: PMSF, phenylmethanesulfonyl fluoride; SBTI, 
soybean trypsin inhibitor; MCA, methylcoumaryl amide 
which has a high molecular mass and degrades type 
IV collagen specifically. 
2. MATERIALS AND METHODS 
2.1. Materials 
DE-52 was purchased from Whatman Paper (Maidstone, 
England). Hydroxyapatite was from Bio-Rad (Richmond, 
USA) and Sepharose 6B from Pharmacia (Milwaukee, USA). 
Trypsin, casein, hemoglobin, bovine serum albumin, soybean 
trypsin inhibitor and aprotinin were obtained from Sigma (St. 
Louis, USA). Leupeptin, pepstatin, antipain, E-64, chymo- 
statin, elastatinal and several synthetic peptide substrates were 
from the Peptide Institute (Osaka). Human plasma fibronectin 
was obtained from Bethesda Research (Scotland) and murine 
laminin from Collaborative Research (Lexington, USA). Type 
I, II, III and V collagens were obtained from Koken (Tokyo). 
Type IV collagen from human placenta nd bovine anterior lens 
capsule was from Koken or Sigma and from Nitta Gelatin 
(Osaka). 
2.2. Preparation of isotopically labeled type IV collagen 
‘H-labeled type IV collagen was prepared according to Hu et 
al. [13] and Means and Feeney [14]. The specific count of the 
labeled collagen was 2100 cpm/,ug. 
2.3. Assay of type IV collagen-degrading enzyme activity 
40 pl of enzyme solution was activated by trypsin (17 pg/ml) 
with 360~1 of 50 mM Tris-HCl buffer (pH 7.6) containing 
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20 mM NaC1 and 5 mM CaC12 (basal buffer) at 37°C for 
10 min. Activation was stopped by addition of 50/~1 of a solu- 
tion of SBTI (400/zg/ml) and aprotinin (5000 U/ml), followed 
by 7.5/~g 3H-labeled type IV collagen as a substrate. The reac- 
tion was allowed to proceed for 18 h at 37°C and stopped by 
the addition of 100 pl of a solution of 10070 trichloroacetic a id 
and 5% tannic acid. After 400/~1 of the supernatant had been 
dissolved in 5 ml Aquasol-2, the radioactivity was counted. 1 
unit of enzyme activity was expressed as the enzyme degrading 
0.5 pg type IV collagen at 37°C for 18 h. 
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2.4. Purification of the protease 
Human stomach adenocarcinoma tissue (58 g) obtained by 
surgical operation was minced and homogenized in a Waring 
blender with 5-fold volumes of basal buffer (pH 7.6) containing 
500 mM NaCI, and sonicated. The enzyme solution was cen- 
trifuged at 12000rpm for 20min. The supernatant was 
precipitated by 25-55% (NH4)zSO4 saturation, and the pellet 
obtained after centrifugation was dissolved and dialyzed vs 
basal buffer. The dialyzed enzyme solution was applied to a 
DE-52 column (3.6 x 25 cm) and equilibrated with basal buf- 
fer. The column was washed with the same buffer and then 
eluted with basal buffer (pH 7.6) containing 80 mM NaCI. Ac- 
tive fractions were collected and concentrated by 0-80°70 
(NH4)2SO4 saturation extensively, dialyzed vs 50 mM Tris-HCl 
buffer (pH 7.6) and applied to a hydroxyapatite column (2.6 x 
8.0 cm). The column was equilibrated with 50 mM Tris-HCl 
buffer (pH 7.6) and eluted with the same buffer containing 
10 mM sodium phosphate buffer. The enzyme solution was 
concentrated using (NH4)2SO4 and then dialyzed vs basal buf- 
fer. This was applied to a Sepharose 6B column (1.6 x 90 cm) 
equilibrated with basal buffer containing 0.2070 polyethylene 
glycol and eluted with the same buffer. The enzyme activity ap- 
peared as a single peak. Active fractions were pooled, concen- 
trated and used for the following studies. 
2.5. pH dependency 
In order to ascertain the pH optimum of the purified enzyme, 
50 mM acetate buffer (pH 3.5-6.0) and 50 mM Tris-HCl buf- 
fer (pH 6.5-9.0) were used. After trypsin activation of the 
purified enzyme as described above the assay was performed us- 
ing each buffer solution instead of basal buffer. The pH of the 
reaction mixture was confirmed after incubation. 
2.6. Substrate specificity 
The substrate specificity of the purified protease was studied 
Table 1 
Purification of high molecular mass metalloprotease 
Procedure 
6 ~b 2'o 3b 
Trypsin Conc. (pg/ml) 
Total Total Specific Relative 
protein activity activity purifica- 
(mg) (U x 10 -3) (U x l0 -3) tion (-fold) 
25-55070 (NH4)2SO4 
precipitation 507 101 0.2 1 
DEAE-cellulose 28 1389 50 250 
Hydroxyapatite 6.8 503 74 370 
Sepharose 6B 0.26 446 1662 8310 
using various s)/nthetic and native substrates. After activation 
of the protease (600 U) with trypsin, the standard assay was 
performed using synthetic substrates, for example Bz-Arg- 
MCA, Boc-Phe-Ser-Arg-MCA, Suc-Ala-Ala-Pro-Phe-MCA, 
Z-Arg-Arg-MCA, Z-Phe-Arg-MCA, Suc-Gly-Pro-Leu-Gly- 
Pro-MCA, Suc-AIa-Pro-Ala-MCA, Suc-GIy-Pro-MCA and 
Suc-AIa-AIa-Phe-MCA, as substrates instead of 3H-labeled 
type IV collagen. The reaction was carried out for 6 h at 37°C 
until the addition of trichloroacetic and tannic acids, and then 
the fluorescence of the supernatant was measured. To deter- 
mine the specificity of the protease with respect o native 
substrate, proteins uch as type I, II, III, V collagens, laminin, 
fibronectin, casein, albumin and hemoglobin were used as 
substrates. The mixture of activated enzyme and each native 
substrate was allowed to react for 18 h at 37°C. Subsequently, 
the mixture was treated with SDS for 5 rain at 95°C and applied 
to SDS-polyacrylamide gel electrophoresis. On comparison 
with the control (without enzyme), it was established whether or 
not the bands of substrate had been degraded. 
2.7. Inhibition of enzyme activity 
Inhibition of enzyme activity by various protease inhibitors 
was studied. Each inhibitor was added to activated enzyme 
solution and the reaction allowed to proceed for 18 h at 37°C. 
The following steps were the same as the standard assay de- 
scribed above. 
3. RESULTS 
3.1. Purification o f  type IV  collagen-degrading 
protease 
Representat ive  steps in  the  pur i f i ca t ion  o f  type  
IV  co l lagen-degrad ing  protease  f rom human 
s tomach carc inoma t issue are summar ized  in tab le  
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Fig.l. Trypsin activation of purified enzyme. The enzyme 
solution, containing trypsin added at various concentrations, 
was activated and assayed. Control was carried out without 
trypsin. 
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Fig.2. pH dependency. 50 mM acetate buffer (pH 3.5-6.0) and 
50 mM Tris-HCl buffer (pH 6.5-9.0) were used instead of basal 
buffer during assay. 
1. By means of this procedure, approx. 8300-fold 
purification of the protease was achieved. After 
DEAE-cellulose column chromatography, the 
total activity of the protease was increased. In 
Sepharose 6B column chromatography, the peak 
of enzyme activity was eluted as a single peak be- 
tween those of blue dextran and ferritin. When this 
final enzyme preparation was applied to HPLC gel 
filtration (TSK G4OOOSW column), the enzyme ac- 
tivity was also eluted as a single peak and its 
molecular mass was estimated to be 1 MDa using 
blue dextran, IgM, ferritin and bovine serum 
albumin as standards. This value remained un- 
Table 2 
Inhibitor sensitivity 
Compounds (final concentration) % inhibition 
Leupeptin (10 yg/ml) 0 
Antipain (10 pg/ml) 11 
PMSF (5 mM) 10 
Elastatinal (1 pg/ml) 0 
(10 fig/ml) 36 
Chymostatin (10 ag/ml) 10 
E-64 (10 pg/ml) 0 
Pepstatin (10 pg/ml) 0 
Phosphoramidon (0.5 mM) 51 
EDTA (5 mM) 97 
(10 mM) 100 
o-Phenanthroline (IO mM) 100 
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changed in the presence of 0.1% Triton X-100, 
Brij and 1 M NaCl. The final enzyme preparation 
was inactive and was activated by trypsin (fig.1). 
3.2. pH dependency 
Fig.2 shows the pH dependence of the purified 
enzyme. The pH optimum of this enzyme was be- 
tween pH 7.0 and 8.0, the maximum activity being 
around pH 7.6. 
Fig.3. (a) Substrate specificity (1). Substrate specificity was 
studied using SDS-PAGE. Type I, II, III and V collagens were 
used as substrates and were incubated with enzyme. The 
mixture was then applied to a 7% a&amide gel. Lanes: 1, type 
I collagen alone; 2, type I + enzyme; 3, type II alone; 4, type 
II + enzyme; 5, type III alone; 6, type III + enzyme; 7, type V 
alone; 8, type V + enzyme. (b) Substrate specificity (2). Type 
IV collagen (from bovine placenta and bovine anterior lens 
capsule) was used as substrate, and SDS-PAGE was carried out 
using 7% acrylamide gel. Lanes: 1, type IV collagen from 
bovine placenta alone; 2, type IV from bovine placenta + 
enzyme; 3, type IV from bovine anterior lens capsule alone; 4, 
type IV from bovine anterior lens capsule + enzyme. 
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3.3. Inhibition of enzyme activity 
Table 2 lists the effects of several protease in- 
hibitors on the activity of the protease. The 
purified enzyme was inhibited by only EDTA, o- 
phenanthroline and phosphoramidon which are ef- 
fective inhibitors of metalloprotease, but was in- 
sensitive to leupeptin, antipain, chymostatin, E-64, 
pepstatin and PMSF. Elastatinal (10 pg/ml) in- 
hibited 36% of the protease activity. 
3.4. Substrate specificity 
Specific degradation of various kinds of native 
substrates by the purified enzyme was determined 
through SDS-polyacrylamide gel electrophoresis. 
Type I, II, III and V collagens, fibronectin, 
laminin, casein, albumin and hemoglobin were in- 
cubated with activated enzyme for 18 h at 37”C, 
however the main bands of all substrates did not 
vary. On the other hand, type IV collagen (from 
bovine placenta and bovine anterior lens capsule) 
was also incubated with enzyme. The 100 and 
90 kDa bands of each type IV collagen disap- 
peared, and other chains were also partially 
degraded (fig.3). 
The enzyme did not cleave any synthetic peptide 
substrates used as substrate. 
4. DISCUSSION 
The purification of a protease from human 
malignant umor has been described. The protease 
has a high molecular mass (1 MDa) and degrades 
type IV collagen specifically. During purification, 
especially after DEAE-cellulose column chroma- 
tography, the total activity increased. This 
phenomenon shows that one or more native in- 
hibitors against this enzyme might exist in tumor 
tissue, and were removed by the purification step. 
We also found that this enzyme existed as a latent 
form and was activated by trypsin. Inhibition by 
EDTA, o-phenanthroline and phosphoramidon 
suggests that this enzyme is a metalloprotease. 
These characteristics are similar to those of other 
collagenase type proteases reported. From the 
specificity of the purified protease with respect to 
native substrates, it is inferred that this enzyme dif- 
fers from gelatinase, proteoglycanase and col- 
lagenase type proteases which degrade basement 
membrane components. Gelatinase cleaves gelatin, 
casein, elastin, and type IV and V collagens [15]. 
Proteoglycanase cleaves proteoglycan, laminin, 
fibronectin and type I and IV collagens [9]. The 
protease from rabbit bone culture medium 
degrades type IV and V collagens, gelatin, laminin 
and fibronectin [8,9], and that from human 
rheumatoid synovial fibroblast culture medium 
gives rise to degradation of proteoglycan, laminin, 
gelatin, fibronectin and type IV collagen [4]. The 
proteases from human polymorphonuclear leuko- 
cyte granules and rat mast cells also degraded type 
IV collagen, however these are serine proteases 
[S-7]. Furthermore, all other type IV collagen- 
degrading proteases except our enzyme have 
molecular masses below 100 kDa. Based on these 
results, our enzyme seems to be a new protease 
derived from human carcinoma tissue. In addition, 
it is believed that this protease degrades type IV 
collagen and destroys the function of the basement 
membrane, resulting in susceptibility to tumor in- 
vasion and metastasis. It is very interesting that the 
type IV collagen-degrading protease exists in 
malignant tumor tissue, since the first step in the 
mechanism of tumor invasion and metastasis in- 
volves destruction of the basement membrane. 
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